Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mod who wrote (5399)	9/25/1998 12:53:00 PM
From: Steve Fancy	Read Replies (2) of 6136

Thanks Dennis. Here's some info on Viramune... Boehringer Ingelheim's Viramune Treats First-Line HIV/AIDS Dow Jones Newswires SAN DIEGO -- Boehringer Ingelheim KG said a combination of drugs that includes its Viramune product has proven to be an effective first-line treatment for HIV/AIDS. In a press release Friday, the company said the six-month trial, which was presented at an international conference on infectious diseases, studied the combination of its non-nucleoside reverse transcriptase inhibitor, Viramune, and the nucleoside analogues d4T and ddI. The study showed that a protease-sparing regimen of Viramune, d4T and ddI achieves "significant" viral load reductions. Specifically, the findings showed that at six months, 64% of patients, or 30 out of 47, have levels of HIV that cannot be detected by a viral load test that measures lower than 50 copies/ml in the blood. Boehringer said that with a twice-daily regimen of the drugs, which require only six to seven pills, the results are comparable to those achieved with protease inhibitors.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next